Helius Medical Technologies (HSDT) AI Stock Analysis

• Market Cap: $77.23M
• Dividend Yield: N/A
• Average Volume (3M): 1.55M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.11
• Revenue Growth: 87.45%
• EPS Growth: 72.30%
• Country: US
• Employees: 21
• Sector: Financial
• Sector Strength: 70
• Industry: Medical - Devices
• EPS (TTM): -32.89
• Shares Outstanding: 41,301,400
• 10 Day Avg. Volume: 1,311,391
• 30 Day Avg. Volume: 1,547,142
• PEG Ratio: 2.86
• Price to Book (P/B): 1.29K
• Price to Sales (P/S): 2618.59
• P/FCF Ratio: -123.27
• Enterprise Value/Market Cap: -0.63
• Enterprise Value/Revenue: -51.74
• Enterprise Value/Gross Profit: -104.26
• Enterprise Value/Ebitda: 0.13
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -64.5
• Revenue Forecast (FY): $655.00K

• Rating: 41 Neutral
• Price Target: $2.00 ▼(-37.69% Downside)
• Action: Reiterated Date: 02/04/26
• Date: Action: Reiterated 02/04/26

The score is pressured primarily by weak financial performance (large ongoing losses, persistent cash burn, and negative equity) and bearish technicals (below major moving averages with negative MACD). Earnings-call positives (significant fundraising and favorable PoNS study outcomes) provide some offset, but the magnitude of losses and higher expenses limit the overall rating; valuation offers limited support due to negative earnings and no stated dividend yield.

Positive Factors

Clinical Evidence / Regulatory Progress

Positive clinical outcomes supporting an FDA 510(k) submission represent durable regulatory progress and lower commercialization risk. Clearance could materially expand reimbursable use, increase adoption by clinicians and patients, and strengthen the firm’s ability to commercialize the PoNS platform over the next several quarters.

Revenue Growth & Improved Gross Margin

A sharp TTM revenue rebound combined with a ~50% gross margin indicates improving unit economics and growing market acceptance. If sustained, this trend supports scalable revenue growth and provides a clearer path to narrowing operating losses as fixed costs are leveraged across higher sales volumes.

Low Financial Leverage

Near-zero debt reduces interest burden and lowers default risk, giving management flexibility to invest in commercialization, clinical programs, or partnerships. Low leverage improves optionality for future financings and strategic initiatives without immediate pressure from creditors.

Negative Factors

Persistent Cash Burn

Sustained negative operating and free cash flow (~-$12.7M TTM) is a durable constraint: it requires recurring external funding, increases dilution risk, and forces management to prioritize cash preservation over growth investments. Continued cash burn threatens runway absent successful commercialization or financing.

Negative Stockholders' Equity

Negative shareholders’ equity signals accumulated losses and weak capitalization. This restricts financing alternatives, can complicate reimbursement or partner agreements, and may deter strategic counterparties. Absent recapitalization, negative equity is a structural barrier to long-term stability.

Sustained Operating Losses

Deep, persistent operating losses show the business has not reached a sustainable earnings model. Even with revenue growth, high operating losses mean break-even remains uncertain; ongoing deficits necessitate capital raises and increase execution risk for commercialization and scaling efforts.

Helius Medical Technologies Business Overview & Revenue Model

Company Description

Solana Co. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain’s ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational portable neuromodulation stimulator, that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded on March 13, 2014 and is headquartered in Newtown, PA.

How the Company Makes Money

Helius Medical Technologies generates revenue primarily through the sale of its medical devices, specifically its portable neuromodulation device (PND), which is utilized in clinical settings and by patients at home. The company may also engage in partnerships with healthcare providers and institutions to facilitate the distribution of its products, thereby expanding its market reach. Additionally, HSDT may explore revenue streams through reimbursement agreements with insurance companies, allowing patients to access their technology with financial support. The ongoing development of new applications for its technology and potential collaborations with pharmaceutical companies further contribute to its revenue potential.

Helius Medical Technologies Financial Statement Overview

Summary

Despite a sharp TTM revenue rebound and improved gross margin (~50%), results are dominated by extremely weak profitability (deeply negative EBIT/EBITDA and massively negative net margin), persistent cash burn (TTM FCF about -$12.7M), and a weakened balance sheet with negative stockholders’ equity. Low/near-zero debt is a mitigating positive but does not offset funding dependence risk.

Income Statement

TTM (Trailing-Twelve-Months) revenue rebounded sharply (up ~219%), and gross margin improved to ~50%, a meaningful positive versus several prior years. However, profitability is extremely weak: EBIT and EBITDA are deeply negative and the TTM net margin is massively negative, driven by outsized losses relative to a very small revenue base. Annual results from 2020–2024 also show persistent operating losses and generally negative net margins, indicating the business has not yet demonstrated a sustainable earnings model.

Balance Sheet

Debt levels appear very low (near-zero debt across periods, including zero debt in TTM), which reduces financial leverage risk. The major concern is capitalization: TTM stockholders’ equity is negative, which is a significant balance-sheet red flag and can limit financing flexibility. Earlier annual periods showed positive equity, suggesting deterioration into negative equity more recently.

Cash Flow

Cash burn remains heavy and consistent: operating cash flow and free cash flow are negative across every annual period and in TTM (about -$12.7M TTM). Free cash flow has shown occasional improvements (including modest positive growth in TTM), but cash generation is still far from breakeven, and cash outflows remain large relative to the company’s revenue scale.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	941.00K	520.00K	644.00K	787.00K	522.00K	661.00K
Gross Profit	467.00K	-62.00K	61.00K	324.00K	224.00K	-90.00K
EBITDA	-368.40M	-13.80M	-12.11M	-14.50M	-17.82M	-13.65M
Net Income	-370.37M	-11.74M	-8.85M	-14.07M	-18.13M	-14.13M
Balance Sheet
Total Assets	475.92M	3.54M	7.69M	17.29M	14.10M	6.55M
Cash, Cash Equivalents and Short-Term Investments	124.05M	1.09M	5.18M	14.55M	11.01M	3.33M
Total Debt	0.00	12.00K	57.00K	110.00K	3.00K	91.00K
Total Liabilities	628.31M	2.48M	5.34M	9.14M	2.85M	2.68M
Stockholders Equity	-152.39M	1.06M	2.35M	8.15M	11.26M	3.87M
Cash Flow
Free Cash Flow	-12.71M	-11.05M	-10.45M	-14.33M	-13.44M	-11.80M
Operating Cash Flow	-12.71M	-11.04M	-10.42M	-14.31M	-13.39M	-11.74M
Investing Cash Flow	-267.38M	-5.00K	-29.00K	-11.00K	-56.00K	-9.00K
Financing Cash Flow	400.68M	6.95M	1.08M	17.87M	21.13M	9.64M

Helius Medical Technologies Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.21
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HSDT, the sentiment is Negative. The current price of 3.21 is above the 20-day moving average (MA) of 2.10, above the 50-day MA of 2.67, and below the 200-day MA of 24.04, indicating a bearish trend. The MACD of -0.25 indicates Negative momentum. The RSI at 38.62 is Neutral, neither overbought nor oversold. The STOCH value of 50.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HSDT.

Helius Medical Technologies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VMD	72 Outperform	$330.76M	26.32	10.53%	―	18.90%	29.22%
Sector *	68 Neutral	$18.00B	11.42	9.92%	3.81%	9.73%	1.22%
OM	51 Neutral	$63.83M	―	-106.20%	―	4.65%	68.71%
SGHT	46 Neutral	$272.82M	-5.76	-57.91%	―	-4.39%	11.70%
CVRX	45 Neutral	$214.70M	-3.99	-91.88%	―	18.44%	25.42%
SNWV	42 Neutral	$208.62M	-14.42	―	―	40.89%	-749.65%
HSDT	41 Neutral	$77.23M	>-0.01	―	―	87.45%	72.30%